Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 279

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 279
---
 Business Combination; 132

• Readiness to be a Public Company. As the Company has previously been a private company and the majority of their executives and employees are located outside the United States, the Company may not have all the different types of employees necessary for it to timely and accurately prepare reports for filing with the SEC. There is a risk that the Company will not be able to hire the right people to fill in these gaps by the time of the Closing or that additional issues could arise after the Closing due to its failure to have hired these people in advance of Closing; and • Other Risk Factors. Various other risk factors associated with the Company’s business, as described in the section entitled “ Risk Factors” appearing elsewhere in this document. After considering the foregoing, the APx Board concluded, in its business judgment, that the potential benefits to APx and APx’s shareholders relating to the Business Combination outweighed the potentially negative factors and risks relating to the Business Combination. Prior SPAC Experience of the Sponsor, the Initial Sponsor and Officers and Directors APx’s Sponsor, Initial Sponsor and officers and directors have extensive experience in capital markets transactions, mergers and acquisitions and business strategy. In addition, Kyle Bransfield, APx’s Chief Executive Officer and Chairman and Chief Executive Officer of the Sponsor, served as director and Chief Executive Officer of Union Acquisition Corp, and Union Acquisition Corp. II, leading the companies through successful mergers with Bioceres Crop Solutions (NASDAQ: BIOX) and Procaps Group (NASDAQ: PROC) in March 2019 and September 2021, respectively. Mr. Bransfield previously served on the board of Procaps Group and sat on the audit committee and the mergers and acquisitions committee. Following Lightjump Acquisition Corp’s successful business combination with Moolec Science Ltd. (NASDAQ: MLEC) in December 2022, Mr. Bransfield now serves as a board member on the compensation and audit committees. Fiduciary Duties of APx’s Officers and Directors Below is a table summarizing the entities to which our officer and directors currently have fiduciary duties, contractual obligations or other material management relationships:

| Individual          |     | Entity                        |     | Entity’s Business                   |     | Affiliation               |
| Kyle Bransfield     |     | APx Acquisition Corp. I       |     | Special purpose acquisition company |     | CEO, Director             |
|                     |     | Moolec Science Ltd.           |     | Food science                        |     | Director                  |